Clinical Trials Logo

Clinical Trial Summary

The study wishes to examine whether "extended" antipsychotic treatment, in this case, antipsychotic treatment every other day, is as effective as daily treatment. It is also evaluating whether there may be differences in terms of side effects. Participants will be randomly assigned to either the treatment as usual group (i.e., taking antipsychotic daily) or the extended dosing group (i.e., taking antipsychotic one day on, one day off). That means, like flipping a coin, there is a 50/50 chance that participants will continue on daily dosing of your antipsychotic or have it switched to every other day dosing. This study will last for 1 year. Participants will be evaluated at the beginning and every two weeks during the first 6 months, with visits once every 4 weeks for the final 6 months. In total, participants will make 22 visits over 52 weeks to the investigator's office. The investigators hypothesize that with ED, there will be no change in symptom severity but improvement in the frequency and severity of side effects, wellbeing, and functioning.


Clinical Trial Description

This is a randomized, double-blind, controlled trial that will compare ED, i.e. alternate day dosing to daily dosing i.e. TAU. Individuals will be randomized to ED or TAU using a permuted block design with a random number generator. The size will be fixed and study personnel blinded to the randomization block size. To maintain a double-blind design, our pharmacy will provide, on an individualized basis, APs at the appropriate dose and placebo where necessary in matching gelatin capsules, packaged in blister packs. The active tablet will be over-encapsulated, and matching placebo will be prepared using the same capsules (filled with lactose). Thus, from the individual subject's position, AP treatment is continued according to the same daily schedule. Further, if their current medication is prescribed in divided doses, this too will be employed during the study. The minimum and maximum doses for Risperidone will be 1 mg and 16mg respectively. The minimum and maximum doses for Olanzapine will be 5 mg and 20mg respectively. Other psychotropic medications prescribed before the study will be permitted, with any changes in dosing during its course documented The trial is 1 year in duration. To prevent bias, the study code will remain blinded until the trial's completion. Study visits will be scheduled every 2 weeks over the first 6 months, in line with the earlier investigation. Thereafter, the visits will be decreased to every 4 weeks, aligning with the schedule routinely observed in our ambulatory clinics. The investigators are asking the following questions: 1. (Non-inferiority) Can additional confirmatory evidence support "extended" AP dosing (ED) as an alternative to continuous administration, i.e. is it as effective clinically? 2. (Superiority) Can the investigators establish clinical benefits (e.g. better tolerability, fewer side effects, such as decreased glucose dysregulation) with ED? Hypothesis: The investigators hypothesize that with ED, there will be no change in symptom severity but improvement in the frequency and severity of side effects, wellbeing, and functioning. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04478838
Study type Interventional
Source Centre for Addiction and Mental Health
Contact Carol Borlido
Phone 416-535-8501
Email carol.borlido@camh.ca
Status Recruiting
Phase Phase 4
Start date June 6, 2022
Completion date September 30, 2028

See also
  Status Clinical Trial Phase
Completed NCT05083377 - Clozapine Use Pattern in the Province of Seville
Recruiting NCT06313918 - Exercise Therapy in Mental Disorders-study N/A
Recruiting NCT06134661 - Accelerated rTMS for Psychomotor Slowing N/A
Completed NCT01433094 - Study on Psychoeducation Enhancing Results of Adherence in Schizophrenia N/A
Terminated NCT05526833 - An Extension Protocol for Patients Who Previously Completed the TMS Pilot Study N/A
Recruiting NCT05982158 - Avatar-mediated Therapy Versus Cognitive Behavioural Therapy for Persisting Experiences of Hearing Voices N/A
Active, not recruiting NCT06175559 - Embedded Narrative in Interactive Game Design for Improving Medication Adherence of Schizophrenia N/A
Active, not recruiting NCT05673941 - "InMotion" - Physical Training With Creative Movement as an Intervention for Adults With Schizophrenia N/A
Recruiting NCT02916810 - TMS for Symptom Reduction in Schizophrenia N/A
Recruiting NCT05958875 - The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. Phase 4
Recruiting NCT03525054 - Semantic and Syntactic Computerized Analysis of Free Speech
Recruiting NCT05389345 - tDCS and Executive Function Training for Schizophrenia N/A
Completed NCT05601050 - Linguistic Predictors of Outcomes in Psychosis
Completed NCT03075202 - Role of an E-cigarette on Smoking Displacement in Smokers With Schizophrenia
Completed NCT03921450 - Overcoming Psychomotor Slowing in Psychosis (OCoPS-P) N/A
Completed NCT06231407 - Increasing Medication Check Participation Through Applying CT-r N/A
Completed NCT04366401 - Efficacy of Prebiotic and Probiotic Dietary Modulation in Schizophrenic Disorders N/A
Completed NCT04612777 - A Trial of "Opening Doors to Recovery" for Persons With Serious Mental Illnesses N/A
Not yet recruiting NCT06191965 - MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction Phase 2/Phase 3
Recruiting NCT04321759 - Comparative Effectiveness of CET vs. SST in SMI (Serious Mental Illness) N/A